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Background: Symptomatic paravalvular leak (PVL) occurs in 1-2% of all patients who undergo valve replacement. Until recently, surgery was 
considered the gold standard of repair. However, given the fact that these are re-operations they carry a significant morbidity and mortality, 
especially for patients with significant co-morbidities. The reported in-hospital mortality is 5%. Percutaneous catheter based closure (PCC) of PVL 
has been recently introduced as a possible alternative method.The purpose of this study is to describe a single center experience in a relatively large 
series of patients with symptomatic PVL who underwent percutaneous closure procedure.
Methods: Thirty eight patients (64% males, 68.2±12 years of age) underwent percutaneous PVL closure with multimodality imaging screening 
and surveillance (which included real-time 3-dimensional transeshophageal echocardiography as well as 4D computed tomographic angiography). 
The mean number of cardiac surgeries was 1.6 and the time since last valve replacement was 29±11 months (range 4-218 months).There were 
paravalvular leaks in 10 aortic and 28 mitral prostheses (26 were bioprostheses and 12 were mechanical). All patients were symptomatic (mean 
NYHA functional class 2.9±0.7). 68% had congestive heart failure and 76% suffered from hemolysis (40% of which required multiple transfusions). 
24% had renal failure.
Results: Successful device deployment was achieved in 92%. More than one leak was observed in 9 patients; these were closed with 2 devices (8 
patients) and 3 devices (one patient).There was one procedure related death (from cardiac tamponade) and one emergency surgery required for 
entrapped device. There were no thrombo-embolic events, device related prosthetic dysfunction or endocarditis. The mean NYHA functional class 
declined (2.2±0.8) and the hemolysis resolved in 83% of the patients. Worse hemolysis was reported in one patient, and new hemolysis was found in 
3 patients.
Conclusions: In this single center experience, percutaneous closure was feasible and relatively safe in symptomatic patients with PVL. It should be 
considered a reasonable alternative to re-operation.
